Explore 3 Stock Ideas & Industry Insights Download Free Report

18889881171
Shopping Cart 0
countryflagUS
Login

Alumis Inc

Healthcare US ALMS

20.39USD
0.31(1.54%)

Last update at 2026-06-04T20:00:00Z

Day Range

20.0020.99
LowHigh

52 Week Range

2.7630.60
LowHigh

Fundamentals

  • Previous Close 20.08
  • Market Cap3143.10M
  • Volume726523
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-438.40800M
  • Revenue TTM24.05M
  • Revenue Per Share TTM0.28
  • Gross Profit TTM 24.05M
  • Diluted EPS TTM-2.86

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Type yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Income before tax -251.88600M -294.23300M -154.99300M -111.93000M
Minority interest - - - -
Net income -243.32500M -294.23300M -154.99300M -111.93000M
Selling general administrative 91.86M 35.20M 20.50M 12.55M
Selling and marketing expenses - - - -
Gross profit 20.55M -3.15200M -1.28400M -0.25000M
Reconciled depreciation 3.50M 3.15M 1.28M 0.25M
Ebit -427.20400M -300.75400M -158.17400M -113.85000M
Ebitda -423.70800M -297.60200M -156.89000M -113.60000M
Depreciation and amortization 3.50M 3.15M 1.28M 0.25M
Non operating income net other - - - -
Operating income -427.20400M -300.75400M -158.17400M -113.85000M
Other operating expenses 451.25M 300.75M 158.17M 113.85M
Interest expense - - - -
Tax provision -8.56100M 0.00000M - -
Interest income 14.18M 12.02M 3.37M 1.99M
Net interest income 14.18M 12.02M 3.37M 1.99M
Extraordinary items - - - -
Non recurring - - - -
Other items - - - -
Income tax expense -8.56100M - - -
Total revenue 24.05M 0.00000M 0.00000M 0.00000M
Total operating expenses 447.76M 297.60M 158.17M 113.60M
Cost of revenue 3.50M 3.15M 1.28M 0.25M
Total other income expense net 175.32M 6.52M 3.18M 1.92M
Discontinued operations - - - -
Net income from continuing ops -243.32500M -294.23300M -154.99300M -111.93000M
Net income applicable to common shares - - - -
Preferred stock and other adjustments - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Type yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total assets 411.94M 340.99M 89.61M 108.17M
Intangible assets 50.96M - - -
Earning assets - - - -
Other current assets 7.65M 16.11M 3.79M 8.98M
Total liab 110.64M 80.89M 53.50M 17.94M
Total stockholder equity 301.30M 260.10M 36.11M 90.23M
Deferred long term liab - - - -
Other current liab 57.08M 39.73M 18.03M 10.32M
Common stock 0.00900M 0.00400M 0.00100M 0.00100M
Capital stock 0.01000M 0.00400M 0.00100M 0.00100M
Retained earnings -901.87600M -658.55100M -364.31800M -209.32500M
Other liab - - - -
Good will - - - -
Other assets - - 0.00000M -
Cash 89.67M 169.53M 46.00M 25.82M
Cash and equivalents - - - -
Total current liabilities 73.32M 50.91M 20.87M 13.35M
Current deferred revenue 1.46M - -1.11800M -1.72000M
Net debt -52.75600M -138.80400M -13.41600M -24.03700M
Short term debt 4.67M 1.56M 1.72M 1.31M
Short long term debt - - - -
Short long term debt total 36.91M 30.72M 32.58M 1.78M
Other stockholder equity 1202.97M 918.61M 25.05M 14.21M
Property plant equipment - - - -
Total current assets 318.23M 306.19M 53.36M 102.56M
Long term investments - - - -
Net tangible assets - - - -
Short term investments 218.83M 118.74M 2.96M 67.25M
Net receivables 2.08M 1.81M 0.61M 0.50M
Long term debt - - - -
Inventory - - - -
Accounts payable 10.11M 9.62M 1.12M 1.72M
Total permanent equity - - - -
Noncontrolling interest in consolidated entity - - - -
Temporary equity redeemable noncontrolling interests - - - -
Accumulated other comprehensive income 0.19M 0.04M 0.00200M -0.12700M
Additional paid in capital - - - -
Common stock total equity - - - -
Preferred stock total equity - - - -
Retained earnings total equity - - - -
Treasury stock - - - -
Accumulated amortization - - - -
Non currrent assets other 7.59M 1.11M 0.00700M 1.14M
Deferred long term asset charges - - - -
Non current assets total 93.71M 34.80M 36.26M 5.61M
Capital lease obligations 36.91M 30.72M 32.58M 1.78M
Long term debt total - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Type yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Investments 238.79M -113.79000M 60.47M -68.75100M
Change to liabilities - - - -
Total cashflows from investing activities 287.88M -113.79000M - -
Net borrowings - - - -
Total cash from financing activities 2.07M 492.37M 89.68M 101.63M
Change to operating activities - - - -
Net income -243.32500M -294.23300M -154.99300M -111.93000M
Change in cash -79.57900M 123.50M 20.18M -75.98400M
Begin period cash flow 170.63M 47.13M 26.95M 101.80M
End period cash flow 91.05M 170.63M 47.13M 25.82M
Total cash from operating activities -369.52300M -255.07800M -129.97500M -107.72200M
Issuance of capital stock 0.00000M 451.78M 89.78M 99.89M
Depreciation 3.50M 3.15M 1.28M 0.25M
Other cashflows from investing activities 49.74M - - -
Dividends paid - - - -
Change to inventory - - - -
Change to account receivables - - - -
Sale purchase of stock -0.01700M - -0.06400M -
Other cashflows from financing activities - 299.05M 89.68M 101.63M
Change to netincome - - - -
Capital expenditures 0.65M 1.73M 4.50M 2.41M
Change receivables - - - -
Cash flows other operating - - - -
Exchange rate changes - - - -
Cash and cash equivalents changes - - - -
Change in working capital 26.32M 14.76M 12.06M -1.91600M
Stock based compensation 43.52M 19.46M 8.62M 5.96M
Other non cash items -190.97500M 1.79M 3.05M 6.37M
Free cash flow -370.17600M -256.81000M -134.47400M -110.12800M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x)
ALMS
Alumis Inc		 0.31 1.54% 20.39 - - 130.69 10.55 120.88
NVO
Novo Nordisk A/S		 1.75 4.17% 43.75 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 1.78 4.22% 44.00 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 13.40 3.13% 441.74 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 9.78 1.58% 628.73 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment of neuroinflammatory and neurodegenerative diseases. It also develops lonigutamab, a monoclonal antibody targeting IGF-1R for the treatment of thyroid eye diseases; and interferon regulatory factor 5 (IRF5) to address immune dysfunction. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. Alumis Inc. was incorporated in 2021 and is headquartered in South San Francisco, California.

Alumis Inc

280 East Grand Avenue, South San Francisco, CA, United States, 94080

Key Executives

Name Title Year Born
Mr. Martin Babler Ph.D. President, CEO & Chairman 1965
Dr. David M. Goldstein Ph.D. Chief Scientific Officer 1966
Mr. Roy C. Hardiman J.D. Chief Business Officer 1960
Mr. John R. Schroer C.F.A. Chief Financial Officer 1965
Ms. Sara Klein Chief Legal Officer & Corporate Secretary 1964
Ms. Claire Langrish Ph.D. Senior VP & Head of Immunology and Translational Science NA
Mr. Philip Nunn Ph.D. Senior VP of Pharmacology & Project Team Leader NA
Dr. Jorn Drappa M.D., Ph.D. Chief Medical Officer 1964
Mr. Mark Bradley Chief Development Officer 1965
Mr. Kolbot By Ph.D. Senior VP & Head of Technical Operations NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.